DSP 7238

Drug Profile

DSP 7238

Alternative Names: DSP-7238

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Class Antihyperglycaemics
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 02 Oct 2009 Pharmacokinetics & pharmacodynamics data from in vitro & preclinical trials in Type-2 diabetes mellitus presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD-2009)
  • 09 Jun 2009 Preclinical safety, pharmacokinetics and pharmacodynamics data presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009) (1132718. 1132719)
  • 09 May 2008 Phase-I clinical trials in Type-2 diabetes mellitus in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top